📘

Definitions

1

Primary/secondary/idiopathic classification of mast cell activation syndrome

Akin et al. (2010) proposed classifying mast cell activation disorders as primary (a clonal mast cell disorder is identified), secondary (a well-defined condition is identified as the cause of mast cell activation), or idiopathic (neither is found). The classification was later extended with combined (both clonal and secondary) and hereditary alpha-tryptasemia-associated categories, and is now referred to as the ECNM-AIM consortium classification.

DIAGNOSTIC_CRITERIA

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"They also proposed a classification of mast cell activation disorders: primary (if a clonal mast cell disorder is identified), secondary (if a well-defined condition is identified as the cause of mast cell activation), and idiopathic"

States the classification this definition records.

◆

Subtypes

2

Idiopathic Mast Cell Activation Syndrome MONDO:0100051

MCAS meeting consensus criteria with no identifiable IgE-mediated or non-IgE trigger and no evidence of a clonal mast cell disorder. This is the subtype this entry's pathophysiology chain principally models.

Secondary Mast Cell Activation Syndrome MONDO:0100006

MCAS in which mast cell activation is attributable to a well-defined IgE-mediated (allergy) or non-IgE (chronic infection, autoimmune or inflammatory disease) trigger, in the absence of a clonal mast cell disorder. Excluding secondary causes is itself a required diagnostic step before an idiopathic-MCAS label can be assigned.

C

Comorbidities

Hypermobile Ehlers-Danlos Syndrome <-> Mast Cell Activation Syndrome

?

Discussions and Knowledge Gaps

1

How much of the clinical/patient-facing "MCAS" label reflects consensus-criteria-confirmed disease versus a broader, unvalidated symptom complex, and what does that mean for prevalence estimates?

KNOWLEDGE GAP mcas_overdiagnosis_underdiagnosis

Attached to

disease#Mast Cell Activation Syndrome prevalence#

A 2024 review frames MCAS explicitly as both overdiagnosed (broad multisystem symptom complexes labeled MCAS without meeting the three consensus criteria) and underdiagnosed (long diagnostic delay before confirmation). A large single-center cohort found only 4.4% of patients referred for suspected mast cell disorders met strict criteria for idiopathic MCAS, far below popular/patient-facing prevalence claims. Because no general-population prevalence study exists, any figure cited for this entry should be read as bounded to a referred, already-selected population, and the underlying question -- how common consensus-criteria-confirmed MCAS actually is in an unselected population -- remains open.

Show evidence (1 reference)

PMID:38851398 SUPPORT REVIEW SYNTHESIS Other

"Whether MCAS is a primary syndrome or exists as a constellation of symptoms in the context of known inflammatory, allergic, or clonal disorders associated with systemic mast cell activation is not well understood"

A 2024 JACI review states the open epistemic status of MCAS as a distinct clinical entity, motivating this knowledge gap.

⚙

Pathophysiology

4

Mast Cell Surface Receptor Engagement

Mast cell activation is triggered either through classical IgE-dependent FcεRI cross-linking by allergen-bound IgE (secondary/allergic MCAS), or through IgE-independent routes -- MRGPRX2 engagement by basic secretagogues/drugs, complement anaphylatoxins C3a/C5a, physical stimuli, or endotoxin -- in idiopathic MCAS where no IgE trigger is identified.

mast cell CL:0000097

Downstream

Downstream Signaling Cascade Activation

Show evidence (2 references)

PMID:42592556 SUPPORT REVIEW SYNTHESIS Other

"The resulting IgE antibodies are secreted by B cells into the systemic circulation, where they bind with high affinity to FcεRI on MCs and basophils."

Establishes the IgE-dependent FcεRI receptor-engagement branch of this node.

PMID:42592556 SUPPORT REVIEW SYNTHESIS Other

"they are activated through innate immune signaling via TLRs, complement components such as C3a and C5a, and drug-induced activation through receptors such as Mas-related G protein-coupled receptor X2 (MRGPRX2)"

Establishes the IgE-independent branch of this node (complement anaphylatoxins C3a/C5a and MRGPRX2), the mechanism relevant to idiopathic MCAS where no IgE trigger is identified.

Downstream Signaling Cascade Activation

Receptor engagement activates PI3K/Akt/mTOR, RAS/MAPK, and JAK/STAT signaling cascades, driving cytoskeletal reorganization and trafficking of secretory granules toward the plasma membrane.

mast cell CL:0000097

protein tyrosine kinase activity GO:0004713

Downstream

Mast Cell Degranulation and Mediator Release

Show evidence (1 reference)

PMID:42592556 SUPPORT REVIEW SYNTHESIS Other

"Major intracellular signaling pathways involved in MC activation are PI3K/Akt/mTOR, RAS/MAPK, and JAK/STAT."

Directly names the three signaling cascades this node describes.

Mast Cell Degranulation and Mediator Release

Regulated exocytosis releases preformed granule contents (histamine, tryptase, heparin) together with newly synthesized lipid mediators (prostaglandin D2, cysteinyl leukotrienes) and cytokines (TNF-alpha, IL-6, IL-13).

mast cell CL:0000097

mast cell degranulation GO:0043303 ↑ INCREASED

Downstream

Multisystem Mediator-Driven Symptom Generation

Show evidence (1 reference)

PMID:23179866 SUPPORT REVIEW SYNTHESIS Other

"Mast cell activation syndrome (MCAS) is a condition with signs and symptoms involving the skin, gastrointestinal, cardiovascular, respiratory, and neurologic systems."

Establishes the multisystem symptom profile that follows from mediator release, the claim this node's downstream edge carries.

Multisystem Mediator-Driven Symptom Generation

Released mediators act at end-organ sites: histamine and PGD2 drive vasodilation, flushing, and hypotension; histamine and leukotrienes contract smooth muscle (bronchoconstriction, GI cramping); increased vascular permeability produces urticaria and angioedema; autonomic engagement produces tachycardia and presyncope -- together the episodic, multisystem clinical picture required by the consensus diagnostic criteria.

Downstream

Flushing

Urticaria

Angioedema

Pruritus

Abdominal pain

Diarrhea

Hypotension

Tachycardia

Dyspnea

Wheezing

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"Typical clinical manifestations: sudden onset episodes with symptoms typical of MCA (see list below), affecting at least two organ systems, and resolving within several hours (often meeting anaphylaxis criteria)"

States the episodic, multi-organ, self-resolving symptom pattern this node produces.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

10

Cardiovascular 4

Urticaria FREQUENT HP:0001025

Temporal: RECURRENT

Show evidence (2 references)

PMID:41272881 SUPPORT Human Clinical

"H1 antihistamines are typically offered as initial treatment, as they can effectively alleviate cutaneous symptoms such as urticaria, angioedema, and histaminergic pruritus"

Confirms urticaria as a characteristic cutaneous mediator-release symptom targeted by first-line therapy.

PMID:38056692 SUPPORT Human Clinical

"The most common clinical presentation during MCAS episodes was mucocutaneous symptoms in patients with iMCAS, especially urticaria or angioedema."

Establishes urticaria/angioedema as the most common presentation in a confirmed idiopathic-MCAS cohort.

Angioedema FREQUENT HP:0100665

Temporal: RECURRENT

Show evidence (1 reference)

PMID:38056692 SUPPORT Human Clinical

"The most common clinical presentation during MCAS episodes was mucocutaneous symptoms in patients with iMCAS, especially urticaria or angioedema."

Establishes angioedema as a leading presentation in confirmed idiopathic MCAS.

Hypotension HP:0002615

Temporal: RECURRENT

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"Cardiovascularobjective evidence or symptoms suggestive of hypotension such as dizziness, confusion, pre-syncope or syncope"

Lists hypotension and its associated presyncopal symptoms among the typical cardiovascular manifestations.

Tachycardia HP:0001649

Temporal: RECURRENT

Show evidence (1 reference)

PMID:23179866 SUPPORT REVIEW SYNTHESIS Other

"Earlier proposed criteria for the diagnosis of MCAS included episodic symptoms consistent with mast cell mediator release affecting two or more organ systems with urticaria, angioedema, flushing, nausea, vomiting, diarrhea, abdominal cramping, hypotensive syncope or near syncope, tachycardia,..."

Lists tachycardia among the episodic mediator-release symptoms in the diagnostic criteria.

Digestive 1

Diarrhea HP:0002014

Temporal: RECURRENT

Show evidence (1 reference)

PMID:23179866 SUPPORT REVIEW SYNTHESIS Other

"Earlier proposed criteria for the diagnosis of MCAS included episodic symptoms consistent with mast cell mediator release affecting two or more organ systems with urticaria, angioedema, flushing, nausea, vomiting, diarrhea, abdominal cramping, hypotensive syncope or near syncope, tachycardia,..."

Lists diarrhea among the episodic mediator-release symptoms in the diagnostic criteria.

Integument 2

Flushing FREQUENT HP:0031284

Temporal: RECURRENT

Show evidence (1 reference)

PMID:23179866 SUPPORT REVIEW SYNTHESIS Other

"Earlier proposed criteria for the diagnosis of MCAS included episodic symptoms consistent with mast cell mediator release affecting two or more organ systems with urticaria, angioedema, flushing, nausea, vomiting, diarrhea, abdominal cramping, hypotensive syncope or near syncope, tachycardia,..."

Lists flushing among the episodic mediator-release symptoms in the diagnostic criteria.

Pruritus VERY_FREQUENT HP:0000989

Temporal: RECURRENT

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"Most commonly, patients will report abrupt onset of skin symptoms consisting of pruritus (commonly diffuse but that may start in the palms and/or soles), flushing, urticaria, or angioedema"

States pruritus as part of the most common presentation of a systemic mast cell activation episode.

Respiratory 2

Dyspnea HP:0002094

Temporal: RECURRENT

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"respiratory symptoms may also be reported, such as dyspnea, oxygen desaturation, severe nasal congestion, watery rhinorrhea, or sneezing"

Lists dyspnea among the typical respiratory manifestations of a mast cell activation episode.

Wheezing HP:0030828

Temporal: RECURRENT

Show evidence (1 reference)

PMID:23179866 SUPPORT REVIEW SYNTHESIS Other

"Earlier proposed criteria for the diagnosis of MCAS included episodic symptoms consistent with mast cell mediator release affecting two or more organ systems with urticaria, angioedema, flushing, nausea, vomiting, diarrhea, abdominal cramping, hypotensive syncope or near syncope, tachycardia,..."

Lists wheezing among the episodic mediator-release symptoms in the diagnostic criteria.

Constitutional 1

Abdominal pain HP:0002027

Temporal: RECURRENT

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"Gastro-intestinalabdominal cramping, diarrhea or vomiting"

Lists abdominal cramping among the typical episodic gastrointestinal manifestations.

🧬

Genetic Associations

1

TPSAB1 (Genetic modifier: germline TPSAB1 (alpha-tryptase) copy-number gain (hereditary alpha-tryptasemia) is not itself a cause of MCAS but raises basal serum tryptase and heightens mediator-symptom severity and anaphylaxis risk when co-occurring with clonal or secondary mast cell disease.)

Gene: TPSAB1 hgnc:12019 relationship_type: MODIFIER variant_origin: GERMLINE

Show evidence (2 references)

PMID:27749843 SUPPORT PRIMARY RESULT Human Clinical

"we report the identification of germline duplications and triplications in the TPSAB1 gene encoding α-tryptase that segregate with inherited increases in basal serum tryptase levels in 35 families presenting with associated multisystem complaints"

Establishes the germline TPSAB1 copy-number gain as the genetic basis of hereditary alpha-tryptasemia and its multisystem symptom association.

PMID:27749843 SUPPORT Human Clinical

"Individuals harboring alleles encoding three copies of α-tryptase had higher basal serum levels of tryptase and were more symptomatic than those with alleles encoding two copies, suggesting a gene-dose effect."

Demonstrates the gene-dose relationship between TPSAB1 copy number and symptom severity that underlies the modifier (not causal) role modeled here.

💊

Medical Actions

6

H1/H2 Antihistamines

Action: Pharmacotherapy NCIT:C15986

Agent: cetirizine CHEBI:3561 famotidine CHEBI:4975

Platform: Small molecule

Second-generation H1-antihistamines are first-line prophylactic therapy, often up-dosed to four times the standard dose; H2-antihistamines are added empirically for gastrointestinal symptoms.

Mechanism Target:

Multisystem Mediator-Driven Symptom Generation — Blocks histamine receptor-mediated end-organ effects of released mediators.

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"H1 antihistamines are typically offered as initial treatment, as they can effectively alleviate cutaneous symptoms such as urticaria, angioedema, and histaminergic pruritus"

Establishes H1-antihistamines as first-line therapy for cutaneous mediator-release symptoms.

Leukotriene Receptor Antagonist

Action: Pharmacotherapy NCIT:C15986

Agent: montelukast CHEBI:50730

Platform: Small molecule

Montelukast is used for symptoms attributable to cysteinyl leukotrienes, added after antihistamines.

Mechanism Target:

Multisystem Mediator-Driven Symptom Generation — Blocks cysteinyl leukotriene receptor-mediated end-organ effects.

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"a recent observational study of 31 patients with idiopathic MCAS reported that LTRA was the second most commonly used drug for symptom control after anti-H1"

Documents leukotriene receptor antagonists as second-line agents after antihistamines in idiopathic MCAS.

Oral Cromolyn

Action: Pharmacotherapy NCIT:C15986

Agent: disodium cromoglycate CHEBI:128458

Platform: Small molecule

Mast cell stabilizer used for persistent gastrointestinal symptoms despite antihistamines.

Mechanism Target:

Mast Cell Degranulation and Mediator Release — Mast cell-stabilizing effect on degranulation, mechanism not fully established.

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"Oral cromolyn, which is the only formulation available in Canada, may be considered for individuals with persistent GI symptoms associated with MCAS episodes despite the use of anti-H1 and anti-H2"

Establishes cromolyn as an add-on therapy for persistent GI symptoms.

Ketotifen

Action: Pharmacotherapy NCIT:C15986

Agent: ketotifen CHEBI:92511

Platform: Small molecule

A first-generation H1-antihistamine with mast cell-stabilizing properties, used in patients who fail to be controlled with high-dose second-generation H1-antihistamines. Introduced at low dose and taken at bedtime given its sedating effect.

Mechanism Target:

Mast Cell Degranulation and Mediator Release — Mast cell-stabilizing effect, in addition to H1-receptor antagonism.

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"many experts suggest using ketotifen in patients who fail to be controlled with high-dose second generation antiH1"

Establishes ketotifen as a step-up therapy after high-dose second-generation H1-antihistamines.

Omalizumab

Action: Pharmacotherapy NCIT:C15986

Agent: omalizumab NCIT:C29299

Platform: Monoclonal antibody

Anti-IgE monoclonal antibody used for persistent or severe idiopathic MCAS refractory to antihistamines and mast cell stabilizers; case evidence supports efficacy even at low monthly doses.

Mechanism Target:

Mast Cell Surface Receptor Engagement — Blocks free IgE binding to FcεRI on mast cells and basophils, downregulating the receptor and reducing IgE-dependent activation.

Show evidence (1 reference)

PMID:31576204 SUPPORT Human Clinical

"Low-dose omalizumab treatment has successfully led to a 5-year, sustained clinical response, controlled debilitating symptoms of mast cell activation and allowed for reintroduction and long-term maintenance of bee venom subcutaneous immunotherapy."

Documents sustained clinical response to low-dose omalizumab in a confirmed idiopathic non-clonal MCAS case.

Epinephrine for Acute Anaphylaxis

Action: Pharmacotherapy NCIT:C15986

Agent: epinephrine CHEBI:33568

Platform: Small molecule

First-line emergency treatment for anaphylaxis-grade mediator-release episodes.

Mechanism Target:

Multisystem Mediator-Driven Symptom Generation — Counteracts the hemodynamic and airway effects of released mediators.

Target Phenotypes: Hypotension HP:0002615

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"Self-administered epinephrine is the cornerstone treatment for acute episodes, especially those meeting criteria for anaphylaxis, given its rapid onset of action and efficacy"

Establishes epinephrine as first-line emergency treatment for anaphylaxis-grade episodes.

🌍

Environmental Factors

2

Alcohol consumption

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"a challenge with the full meal—ideally including cofactors such as alcohol, NSAIDs, or exercise, if they were present—can be conducted"

Names alcohol as a recognized cofactor/trigger of mast cell activation episodes, tested for directly in the diagnostic workup.

Mechanism Target:

TRIGGERS Mast Cell Surface Receptor Engagement — Alcohol is a recurrent, well-documented trigger of acute mast-cell mediator release episodes in MCAS patients.

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"a challenge with the full meal—ideally including cofactors such as alcohol, NSAIDs, or exercise, if they were present—can be conducted"

Names alcohol as a recognized cofactor/trigger of mast cell activation episodes, tested for directly in the diagnostic workup.

NSAID exposure

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"The next step is to exclude secondary causes of mast cell activation, particularly cofactor-dependent food allergy and nonsteroidal anti-inflammatory drug hypersensitivity."

Names NSAID hypersensitivity as a well-defined secondary trigger of mast cell activation.

Mechanism Target:

TRIGGERS Mast Cell Surface Receptor Engagement — NSAID hypersensitivity is one of the well-defined secondary causes of mast cell activation that must be excluded before an idiopathic-MCAS label can be assigned.

Show evidence (1 reference)

PMID:41272881 SUPPORT Human Clinical

"The next step is to exclude secondary causes of mast cell activation, particularly cofactor-dependent food allergy and nonsteroidal anti-inflammatory drug hypersensitivity."

Names NSAID hypersensitivity as a well-defined secondary trigger of mast cell activation.

🔬

Biochemical Markers

1

🔬

Diagnosis

2

Consensus diagnostic criteria (Akin, Valent, Metcalfe 2010; refined 2019-2020)

All three criteria are required: episodic symptoms consistent with mast cell mediator release affecting two or more organ systems; an event-related increase in a validated serum or urinary mediator marker (preferably tryptase meeting or exceeding baseline x 1.2 + 2 ng/mL, drawn within four hours of an episode); and a decrease in frequency or severity, or resolution, of symptoms with anti-mediator therapy. A clonal mast cell disorder and well-defined secondary causes must be excluded before the idiopathic label is assigned.

Markers: Event-related serum tryptase rise; urinary N-methylhistamine; urinary 11-beta-prostaglandin F2alpha

Show evidence (2 references)

PMID:21035176 SUPPORT REVIEW SYNTHESIS Other

"patients with a presumptive diagnosis of “MCAS” must have two or more of the organ manifestations of mast cell activation such as flushing, urticaria, diarrhea, wheezing. The diagnosis requires that a patient has evidence of an elevation in mediators such as serum tryptase, 24-hour..."

Source of the original 2010 mediator-marker and multi-organ criterion this diagnosis record captures.

PMID:41272881 SUPPORT Human Clinical

"Significant elevation if level is at least 120% + 2 compared to baseline"

States the refined quantitative event-related tryptase-rise threshold.

Exclusion of clonal and secondary causes

Before an idiopathic-MCAS diagnosis can be assigned, a well-defined secondary cause of mast cell activation (food allergy, cofactor-dependent allergy, NSAID hypersensitivity, chronic infection or inflammatory disease) must be excluded, and a clonal mast cell disorder must be investigated (baseline tryptase, peripheral-blood KIT p.D816V testing, mast cell clonality prediction score, and bone marrow biopsy when clonality risk is high).

Markers: Baseline serum tryptase; peripheral-blood KIT p.D816V mutation testing; mast cell clonality prediction score

Show evidence (2 references)

PMID:41272881 SUPPORT Human Clinical

"In patients with idiopathic anaphylaxis, evaluation for a clonal mast cell disorder is recommended. This includes measuring baseline serum tryptase, testing for the KIT p.D816V mutation in peripheral blood (using high-sensitivity assays, if available), and calculating a mast cell clonality..."

States the clonal-disorder workup this diagnosis record captures.

PMID:41272881 SUPPORT Human Clinical

"They also proposed a classification of mast cell activation disorders: primary (if a clonal mast cell disorder is identified), secondary (if a well-defined condition is identified as the cause of mast cell activation), and idiopathic"

States the primary/secondary/idiopathic classification this diagnosis step operationalizes.

📊

Prevalence

1

703 consecutive adult patients referred to a single tertiary center for suspected mast cell disorders

Point Prevalence 4400.0 per 100,000 >1 in 1,000

31 of 703 patients referred for suspected mast cell disorders were confirmed as idiopathic MCAS after full consensus-criteria workup (4.4% of the referred cohort, i.e. 4400 per 100,000 within that cohort). This is a proportion within a highly selected referred population, not a general-population prevalence; the cohort restriction is carried by the `population` field above, not by the prevalence_class band, which reports magnitude only.

Show evidence (1 reference)

PMID:38056692 SUPPORT Human Clinical

"The overall prevalence of iMCAS was 4.4% in the entire cohort, which indicates that iMCAS is an uncommon condition."

Source of the referred-cohort prevalence figure recorded here.

{ }

Source YAML

click to show

name: Mast Cell Activation Syndrome
creation_date: "2026-09-18T03:03:47Z"
category: Complex
synonyms:
- MCAS
- mast cell activation disease
- disorder of mast cell activation
disease_term:
  preferred_term: mast cell activation syndrome
  term:
    id: MONDO:0100004
    label: mast cell activation syndrome
notes: >-
  This entry models the general diagnostic entity of mast cell activation
  syndrome (MCAS) as defined by the 2010/2019-2020 consensus criteria
  (episodic multi-organ symptoms consistent with mast cell mediator release,
  an objective mediator-release biomarker rise during an episode, and
  response to anti-mediator therapy), together with its idiopathic and
  secondary subtypes. Monoclonal (clonal) MCAS -- driven by a somatic KIT
  D816V-type variant and mechanistically and therapeutically distinct -- is
  curated separately as Monoclonal_Mast_Cell_Activation_Syndrome.yaml,
  consistent with the granularity-ladder convention of promoting a
  mechanistically and therapeutically distinct stratum to its own entry.
  Hereditary alpha-tryptasemia (HaT) is modeled here as a genetic modifier
  (elevating basal tryptase and mediator-release severity), not as a causal
  lesion, per its own ICD-10-CM identity (D89.44) and modifier role in the
  literature. The literature is explicit that MCAS is both overdiagnosed
  (broad symptom complexes labeled MCAS without meeting consensus criteria)
  and underdiagnosed (long diagnostic delay); this entry follows the
  consensus-criteria-confirmed definition throughout.
description: >-
  Mast cell activation syndrome (MCAS) is a clinical entity in which mast
  cells release excessive and/or aberrant quantities of mediators (histamine,
  tryptase, prostaglandin D2, cysteinyl leukotrienes, heparin, and cytokines)
  in response to physical, chemical, immunologic, or psychological triggers,
  producing recurrent, episodic, multisystem symptoms without the mast-cell
  proliferation seen in mastocytosis. It is subclassified as idiopathic (no
  identifiable trigger or clonal marker), secondary (a well-defined
  IgE-mediated or non-IgE trigger such as allergy or chronic
  infection/inflammation is identified), or combined (both a clonal marker
  and a secondary trigger); hereditary alpha-tryptasemia can co-occur with
  any of these as a severity modifier. Diagnosis requires meeting all three
  consensus criteria (episodic multi-organ mediator-release symptoms, an
  event-related rise in a validated mediator marker, and response to
  anti-mediator therapy) and excluding both a clonal mast cell disorder and a
  well-defined secondary cause.
has_subtypes:
- name: Idiopathic MCAS
  display_name: Idiopathic Mast Cell Activation Syndrome
  subtype_term:
    preferred_term: idiopathic mast cell activation syndrome
    term:
      id: MONDO:0100051
      label: idiopathic mast cell activation syndrome
  description: >-
    MCAS meeting consensus criteria with no identifiable IgE-mediated or
    non-IgE trigger and no evidence of a clonal mast cell disorder. This is
    the subtype this entry's pathophysiology chain principally models.
- name: Secondary MCAS
  display_name: Secondary Mast Cell Activation Syndrome
  subtype_term:
    preferred_term: secondary mast cell activation syndrome
    term:
      id: MONDO:0100006
      label: secondary mast cell activation syndrome
  description: >-
    MCAS in which mast cell activation is attributable to a well-defined
    IgE-mediated (allergy) or non-IgE (chronic infection, autoimmune or
    inflammatory disease) trigger, in the absence of a clonal mast cell
    disorder. Excluding secondary causes is itself a required diagnostic
    step before an idiopathic-MCAS label can be assigned.
genetic:
- name: TPSAB1
  gene_term:
    preferred_term: TPSAB1
    term:
      id: hgnc:12019
      label: TPSAB1
  association: >-
    Genetic modifier: germline TPSAB1 (alpha-tryptase) copy-number gain
    (hereditary alpha-tryptasemia) is not itself a cause of MCAS but raises
    basal serum tryptase and heightens mediator-symptom severity and
    anaphylaxis risk when co-occurring with clonal or secondary mast cell
    disease.
  relationship_type: MODIFIER
  variant_origin: GERMLINE
  frequency: 4-6% of the general Caucasian population
  features: >-
    Autosomal-dominant germline duplication (most commonly) or triplication
    of the TPSAB1-encoded alpha-tryptase sequence at chromosome 16p13.3,
    highly penetrant for elevated basal serum tryptase but with variable and
    incomplete penetrance for symptomatic multisystem disease.
  evidence:
  - reference: PMID:27749843
    reference_title: "Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number."
    supports: SUPPORT
    quote_role: PRIMARY_RESULT
    evidence_source: HUMAN_CLINICAL
    snippet: "we report the identification of germline duplications and triplications in the TPSAB1 gene encoding α-tryptase that segregate with inherited increases in basal serum tryptase levels in 35 families presenting with associated multisystem complaints"
    explanation: >-
      Establishes the germline TPSAB1 copy-number gain as the genetic basis
      of hereditary alpha-tryptasemia and its multisystem symptom
      association.
  - reference: PMID:27749843
    reference_title: "Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals harboring alleles encoding three copies of α-tryptase had higher basal serum levels of tryptase and were more symptomatic than those with alleles encoding two copies, suggesting a gene-dose effect."
    explanation: >-
      Demonstrates the gene-dose relationship between TPSAB1 copy number and
      symptom severity that underlies the modifier (not causal) role modeled
      here.
pathophysiology:
- name: Mast Cell Surface Receptor Engagement
  biological_scale: MOLECULAR
  description: >-
    Mast cell activation is triggered either through classical IgE-dependent
    FcεRI cross-linking by allergen-bound IgE (secondary/allergic MCAS), or
    through IgE-independent routes -- MRGPRX2 engagement by basic
    secretagogues/drugs, complement anaphylatoxins C3a/C5a, physical stimuli,
    or endotoxin -- in idiopathic MCAS where no IgE trigger is identified.
  cell_types:
  - preferred_term: mast cell
    term:
      id: CL:0000097
      label: mast cell
  downstream:
  - target: Downstream Signaling Cascade Activation
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:42592556
    reference_title: "Pathophysiological Drivers of Mast Cell Activation Syndrome and Implications for Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "The resulting IgE antibodies are secreted by B cells into the systemic circulation, where they bind with high affinity to FcεRI on MCs and basophils."
    explanation: >-
      Establishes the IgE-dependent FcεRI receptor-engagement branch of this
      node.
  - reference: PMID:42592556
    reference_title: "Pathophysiological Drivers of Mast Cell Activation Syndrome and Implications for Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "they are activated through innate immune signaling via TLRs, complement components such as C3a and C5a, and drug-induced activation through receptors such as Mas-related G protein-coupled receptor X2 (MRGPRX2)"
    explanation: >-
      Establishes the IgE-independent branch of this node (complement
      anaphylatoxins C3a/C5a and MRGPRX2), the mechanism relevant to
      idiopathic MCAS where no IgE trigger is identified.
- name: Downstream Signaling Cascade Activation
  biological_scale: CELLULAR
  description: >-
    Receptor engagement activates PI3K/Akt/mTOR, RAS/MAPK, and JAK/STAT
    signaling cascades, driving cytoskeletal reorganization and trafficking
    of secretory granules toward the plasma membrane.
  cell_types:
  - preferred_term: mast cell
    term:
      id: CL:0000097
      label: mast cell
  molecular_functions:
  - preferred_term: protein tyrosine kinase activity
    term:
      id: GO:0004713
      label: protein tyrosine kinase activity
  downstream:
  - target: Mast Cell Degranulation and Mediator Release
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:42592556
    reference_title: "Pathophysiological Drivers of Mast Cell Activation Syndrome and Implications for Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Major intracellular signaling pathways involved in MC activation are PI3K/Akt/mTOR, RAS/MAPK, and JAK/STAT."
    explanation: >-
      Directly names the three signaling cascades this node describes.
- name: Mast Cell Degranulation and Mediator Release
  biological_scale: CELLULAR
  description: >-
    Regulated exocytosis releases preformed granule contents (histamine,
    tryptase, heparin) together with newly synthesized lipid mediators
    (prostaglandin D2, cysteinyl leukotrienes) and cytokines (TNF-alpha,
    IL-6, IL-13).
  cell_types:
  - preferred_term: mast cell
    term:
      id: CL:0000097
      label: mast cell
  biological_processes:
  - preferred_term: mast cell degranulation
    term:
      id: GO:0043303
      label: mast cell degranulation
    modifier: INCREASED
  downstream:
  - target: Multisystem Mediator-Driven Symptom Generation
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:23179866
    reference_title: "Mast cell activation syndrome: a review."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "Mast cell activation syndrome (MCAS) is a condition with signs and symptoms involving the skin, gastrointestinal, cardiovascular, respiratory, and neurologic systems."
    explanation: >-
      Establishes the multisystem symptom profile that follows from mediator
      release, the claim this node's downstream edge carries.
- name: Multisystem Mediator-Driven Symptom Generation
  biological_scale: ORGANISM
  description: >-
    Released mediators act at end-organ sites: histamine and PGD2 drive
    vasodilation, flushing, and hypotension; histamine and leukotrienes
    contract smooth muscle (bronchoconstriction, GI cramping); increased
    vascular permeability produces urticaria and angioedema; autonomic
    engagement produces tachycardia and presyncope -- together the episodic,
    multisystem clinical picture required by the consensus diagnostic
    criteria.
  downstream:
  - target: Flushing
    causal_link_type: DIRECT
  - target: Urticaria
    causal_link_type: DIRECT
  - target: Angioedema
    causal_link_type: DIRECT
  - target: Pruritus
    causal_link_type: DIRECT
  - target: Abdominal pain
    causal_link_type: DIRECT
  - target: Diarrhea
    causal_link_type: DIRECT
  - target: Hypotension
    causal_link_type: DIRECT
  - target: Tachycardia
    causal_link_type: DIRECT
  - target: Dyspnea
    causal_link_type: DIRECT
  - target: Wheezing
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Typical clinical manifestations: sudden onset episodes with symptoms typical of MCA (see list below), affecting at least two organ systems, and resolving within several hours (often meeting anaphylaxis criteria)"
    explanation: >-
      States the episodic, multi-organ, self-resolving symptom pattern this
      node produces.
phenotypes:
- category: Dermatologic
  name: Flushing
  phenotype_term:
    preferred_term: Flushing
    term:
      id: HP:0031284
      label: Flushing
    temporality: RECURRENT
  frequency: FREQUENT
  evidence:
  - reference: PMID:23179866
    reference_title: "Mast cell activation syndrome: a review."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "Earlier proposed criteria for the diagnosis of MCAS included episodic symptoms consistent with mast cell mediator release affecting two or more organ systems with urticaria, angioedema, flushing, nausea, vomiting, diarrhea, abdominal cramping, hypotensive syncope or near syncope, tachycardia, wheezing, conjunctival injection, pruritus, and nasal stuffiness."
    explanation: Lists flushing among the episodic mediator-release symptoms in the diagnostic criteria.
- category: Dermatologic
  name: Urticaria
  phenotype_term:
    preferred_term: Urticaria
    term:
      id: HP:0001025
      label: Urticaria
    temporality: RECURRENT
  frequency: FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "H1 antihistamines are typically offered as initial treatment, as they can effectively alleviate cutaneous symptoms such as urticaria, angioedema, and histaminergic pruritus"
    explanation: >-
      Confirms urticaria as a characteristic cutaneous mediator-release
      symptom targeted by first-line therapy.
  - reference: PMID:38056692
    reference_title: "Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among 703 Patients With Suspected Mast Cell Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common clinical presentation during MCAS episodes was mucocutaneous symptoms in patients with iMCAS, especially urticaria or angioedema."
    explanation: >-
      Establishes urticaria/angioedema as the most common presentation in a
      confirmed idiopathic-MCAS cohort.
- category: Dermatologic
  name: Angioedema
  phenotype_term:
    preferred_term: Angioedema
    term:
      id: HP:0100665
      label: Angioedema
    temporality: RECURRENT
  frequency: FREQUENT
  evidence:
  - reference: PMID:38056692
    reference_title: "Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among 703 Patients With Suspected Mast Cell Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common clinical presentation during MCAS episodes was mucocutaneous symptoms in patients with iMCAS, especially urticaria or angioedema."
    explanation: Establishes angioedema as a leading presentation in confirmed idiopathic MCAS.
- category: Dermatologic
  name: Pruritus
  phenotype_term:
    preferred_term: Pruritus
    term:
      id: HP:0000989
      label: Pruritus
    temporality: RECURRENT
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most commonly, patients will report abrupt onset of skin symptoms consisting of pruritus (commonly diffuse but that may start in the palms and/or soles), flushing, urticaria, or angioedema"
    explanation: >-
      States pruritus as part of the most common presentation of a systemic
      mast cell activation episode.
- category: Gastrointestinal
  name: Abdominal pain
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
    temporality: RECURRENT
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gastro-intestinalabdominal cramping, diarrhea or vomiting"
    explanation: Lists abdominal cramping among the typical episodic gastrointestinal manifestations.
- category: Gastrointestinal
  name: Diarrhea
  phenotype_term:
    preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
    temporality: RECURRENT
  evidence:
  - reference: PMID:23179866
    reference_title: "Mast cell activation syndrome: a review."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "Earlier proposed criteria for the diagnosis of MCAS included episodic symptoms consistent with mast cell mediator release affecting two or more organ systems with urticaria, angioedema, flushing, nausea, vomiting, diarrhea, abdominal cramping, hypotensive syncope or near syncope, tachycardia, wheezing, conjunctival injection, pruritus, and nasal stuffiness."
    explanation: Lists diarrhea among the episodic mediator-release symptoms in the diagnostic criteria.
- category: Cardiovascular
  name: Hypotension
  phenotype_term:
    preferred_term: Hypotension
    term:
      id: HP:0002615
      label: Hypotension
    temporality: RECURRENT
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cardiovascularobjective evidence or symptoms suggestive of hypotension such as dizziness, confusion, pre-syncope or syncope"
    explanation: Lists hypotension and its associated presyncopal symptoms among the typical cardiovascular manifestations.
- category: Cardiovascular
  name: Tachycardia
  phenotype_term:
    preferred_term: Tachycardia
    term:
      id: HP:0001649
      label: Tachycardia
    temporality: RECURRENT
  evidence:
  - reference: PMID:23179866
    reference_title: "Mast cell activation syndrome: a review."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "Earlier proposed criteria for the diagnosis of MCAS included episodic symptoms consistent with mast cell mediator release affecting two or more organ systems with urticaria, angioedema, flushing, nausea, vomiting, diarrhea, abdominal cramping, hypotensive syncope or near syncope, tachycardia, wheezing, conjunctival injection, pruritus, and nasal stuffiness."
    explanation: Lists tachycardia among the episodic mediator-release symptoms in the diagnostic criteria.
- category: Respiratory
  name: Dyspnea
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
    temporality: RECURRENT
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "respiratory symptoms may also be reported, such as dyspnea, oxygen desaturation, severe nasal congestion, watery rhinorrhea, or sneezing"
    explanation: Lists dyspnea among the typical respiratory manifestations of a mast cell activation episode.
- category: Respiratory
  name: Wheezing
  phenotype_term:
    preferred_term: Wheezing
    term:
      id: HP:0030828
      label: Wheezing
    temporality: RECURRENT
  evidence:
  - reference: PMID:23179866
    reference_title: "Mast cell activation syndrome: a review."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "Earlier proposed criteria for the diagnosis of MCAS included episodic symptoms consistent with mast cell mediator release affecting two or more organ systems with urticaria, angioedema, flushing, nausea, vomiting, diarrhea, abdominal cramping, hypotensive syncope or near syncope, tachycardia, wheezing, conjunctival injection, pruritus, and nasal stuffiness."
    explanation: Lists wheezing among the episodic mediator-release symptoms in the diagnostic criteria.
biochemical:
- name: Serum tryptase, event-related rise
  notes: >-
    An acute event-related rise over the patient's own baseline is the
    preferred and most specific validated mediator marker. Elevated baseline
    values alone are not diagnostic of MCAS (they may instead reflect
    hereditary alpha-tryptasemia), and normal baseline values do not exclude
    the diagnosis.
  biomarker_term:
    preferred_term: Elevated total serum tryptase
    term:
      id: HP:0031901
      label: Elevated total serum tryptase
  presence: INCREASED
  readouts:
  - target: Mast Cell Degranulation and Mediator Release
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      An acute-phase tryptase level meeting or exceeding baseline tryptase x
      1.2 + 2 ng/mL, drawn within four hours of a symptomatic episode, is the
      diagnostic biomarker rise required by the consensus criteria.
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Importantly,elevated baseline values in serum tryptase or urinary metabolites are not diagnostic of MCAS, nor do normal values exclude the diagnosis."
    explanation: >-
      States why an event-related rise, not a single baseline value, is the
      diagnostic marker this node records.
environmental:
- name: Alcohol consumption
  exposure_term:
    preferred_term: alcohol consumption
    term:
      id: ECTO:9000027
      label: exposure to ethanol
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a challenge with the full meal—ideally including cofactors such as alcohol, NSAIDs, or exercise, if they were present—can be conducted"
    explanation: >-
      Names alcohol as a recognized cofactor/trigger of mast cell
      activation episodes, tested for directly in the diagnostic workup.
  influences_mechanisms:
  - target: Mast Cell Surface Receptor Engagement
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Alcohol is a recurrent, well-documented trigger of acute mast-cell
      mediator release episodes in MCAS patients.
    evidence:
    - reference: PMID:41272881
      reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "a challenge with the full meal—ideally including cofactors such as alcohol, NSAIDs, or exercise, if they were present—can be conducted"
      explanation: >-
        Names alcohol as a recognized cofactor/trigger of mast cell
        activation episodes, tested for directly in the diagnostic workup.
- name: NSAID exposure
  exposure_term:
    preferred_term: exposure to non-steroidal anti-inflammatory drug
    term:
      id: ECTO:9001720
      label: exposure to non-steroidal anti-inflammatory drug
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The next step is to exclude secondary causes of mast cell activation, particularly cofactor-dependent food allergy and nonsteroidal anti-inflammatory drug hypersensitivity."
    explanation: >-
      Names NSAID hypersensitivity as a well-defined secondary trigger of
      mast cell activation.
  influences_mechanisms:
  - target: Mast Cell Surface Receptor Engagement
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      NSAID hypersensitivity is one of the well-defined secondary causes of
      mast cell activation that must be excluded before an idiopathic-MCAS
      label can be assigned.
    evidence:
    - reference: PMID:41272881
      reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The next step is to exclude secondary causes of mast cell activation, particularly cofactor-dependent food allergy and nonsteroidal anti-inflammatory drug hypersensitivity."
      explanation: >-
        Names NSAID hypersensitivity as a well-defined secondary trigger of
        mast cell activation.
treatments:
- name: H1/H2 Antihistamines
  description: >-
    Second-generation H1-antihistamines are first-line prophylactic therapy,
    often up-dosed to four times the standard dose; H2-antihistamines are
    added empirically for gastrointestinal symptoms.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: cetirizine
      term:
        id: CHEBI:3561
        label: cetirizine
    - preferred_term: famotidine
      term:
        id: CHEBI:4975
        label: famotidine
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Multisystem Mediator-Driven Symptom Generation
    description: Blocks histamine receptor-mediated end-organ effects of released mediators.
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "H1 antihistamines are typically offered as initial treatment, as they can effectively alleviate cutaneous symptoms such as urticaria, angioedema, and histaminergic pruritus"
    explanation: Establishes H1-antihistamines as first-line therapy for cutaneous mediator-release symptoms.
- name: Leukotriene Receptor Antagonist
  description: >-
    Montelukast is used for symptoms attributable to cysteinyl leukotrienes,
    added after antihistamines.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: montelukast
      term:
        id: CHEBI:50730
        label: montelukast
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Multisystem Mediator-Driven Symptom Generation
    description: Blocks cysteinyl leukotriene receptor-mediated end-organ effects.
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a recent observational study of 31 patients with idiopathic MCAS reported that LTRA was the second most commonly used drug for symptom control after anti-H1"
    explanation: Documents leukotriene receptor antagonists as second-line agents after antihistamines in idiopathic MCAS.
- name: Oral Cromolyn
  description: >-
    Mast cell stabilizer used for persistent gastrointestinal symptoms
    despite antihistamines.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: disodium cromoglycate
      term:
        id: CHEBI:128458
        label: disodium cromoglycate
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Mast Cell Degranulation and Mediator Release
    description: Mast cell-stabilizing effect on degranulation, mechanism not fully established.
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Oral cromolyn, which is the only formulation available in Canada, may be considered for individuals with persistent GI symptoms associated with MCAS episodes despite the use of anti-H1 and anti-H2"
    explanation: Establishes cromolyn as an add-on therapy for persistent GI symptoms.
- name: Ketotifen
  description: >-
    A first-generation H1-antihistamine with mast cell-stabilizing
    properties, used in patients who fail to be controlled with high-dose
    second-generation H1-antihistamines. Introduced at low dose and taken at
    bedtime given its sedating effect.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ketotifen
      term:
        id: CHEBI:92511
        label: ketotifen
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Mast Cell Degranulation and Mediator Release
    description: Mast cell-stabilizing effect, in addition to H1-receptor antagonism.
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "many experts suggest using ketotifen in patients who fail to be controlled with high-dose second generation antiH1"
    explanation: Establishes ketotifen as a step-up therapy after high-dose second-generation H1-antihistamines.
- name: Omalizumab
  description: >-
    Anti-IgE monoclonal antibody used for persistent or severe idiopathic
    MCAS refractory to antihistamines and mast cell stabilizers; case
    evidence supports efficacy even at low monthly doses.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: omalizumab
      term:
        id: NCIT:C29299
        label: Omalizumab
  therapeutic_modality: MONOCLONAL_ANTIBODY
  target_mechanisms:
  - target: Mast Cell Surface Receptor Engagement
    description: >-
      Blocks free IgE binding to FcεRI on mast cells and basophils,
      downregulating the receptor and reducing IgE-dependent activation.
  evidence:
  - reference: PMID:31576204
    reference_title: "Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Low-dose omalizumab treatment has successfully led to a 5-year, sustained clinical response, controlled debilitating symptoms of mast cell activation and allowed for reintroduction and long-term maintenance of bee venom subcutaneous immunotherapy."
    explanation: >-
      Documents sustained clinical response to low-dose omalizumab in a
      confirmed idiopathic non-clonal MCAS case.
- name: Epinephrine for Acute Anaphylaxis
  description: >-
    First-line emergency treatment for anaphylaxis-grade mediator-release
    episodes.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: epinephrine
      term:
        id: CHEBI:33568
        label: adrenaline
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Hypotension
    term:
      id: HP:0002615
      label: Hypotension
  target_mechanisms:
  - target: Multisystem Mediator-Driven Symptom Generation
    description: Counteracts the hemodynamic and airway effects of released mediators.
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Self-administered epinephrine is the cornerstone treatment for acute episodes, especially those meeting criteria for anaphylaxis, given its rapid onset of action and efficacy"
    explanation: Establishes epinephrine as first-line emergency treatment for anaphylaxis-grade episodes.
diagnosis:
- name: Consensus diagnostic criteria (Akin, Valent, Metcalfe 2010; refined 2019-2020)
  description: >-
    All three criteria are required: episodic symptoms consistent with mast
    cell mediator release affecting two or more organ systems; an
    event-related increase in a validated serum or urinary mediator marker
    (preferably tryptase meeting or exceeding baseline x 1.2 + 2 ng/mL,
    drawn within four hours of an episode); and a decrease in frequency or
    severity, or resolution, of symptoms with anti-mediator therapy. A
    clonal mast cell disorder and well-defined secondary causes must be
    excluded before the idiopathic label is assigned.
  markers: >-
    Event-related serum tryptase rise; urinary N-methylhistamine; urinary
    11-beta-prostaglandin F2alpha
  evidence:
  - reference: PMID:21035176
    reference_title: "Mast cell activation syndrome: Proposed diagnostic criteria."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "patients with a presumptive diagnosis of “MCAS” must have two or more of the organ manifestations of mast cell activation such as flushing, urticaria, diarrhea, wheezing. The diagnosis requires that a patient has evidence of an elevation in mediators such as serum tryptase, 24-hour N-methylhistamine, or 11βPGF2 during at least two episodes with a negative workup for systemic mastocytosis or clonal mast cell disease in bone marrow biopsies"
    explanation: Source of the original 2010 mediator-marker and multi-organ criterion this diagnosis record captures.
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Significant elevation if level is at least 120% + 2 compared to baseline"
    explanation: States the refined quantitative event-related tryptase-rise threshold.
- name: Exclusion of clonal and secondary causes
  description: >-
    Before an idiopathic-MCAS diagnosis can be assigned, a well-defined
    secondary cause of mast cell activation (food allergy,
    cofactor-dependent allergy, NSAID hypersensitivity, chronic infection or
    inflammatory disease) must be excluded, and a clonal mast cell disorder
    must be investigated (baseline tryptase, peripheral-blood KIT p.D816V
    testing, mast cell clonality prediction score, and bone marrow biopsy
    when clonality risk is high).
  markers: >-
    Baseline serum tryptase; peripheral-blood KIT p.D816V mutation testing;
    mast cell clonality prediction score
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In patients with idiopathic anaphylaxis, evaluation for a clonal mast cell disorder is recommended. This includes measuring baseline serum tryptase, testing for the KIT p.D816V mutation in peripheral blood (using high-sensitivity assays, if available), and calculating a mast cell clonality prediction score."
    explanation: States the clonal-disorder workup this diagnosis record captures.
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "They also proposed a classification of mast cell activation disorders: primary (if a clonal mast cell disorder is identified), secondary (if a well-defined condition is identified as the cause of mast cell activation), and idiopathic"
    explanation: States the primary/secondary/idiopathic classification this diagnosis step operationalizes.
definitions:
- name: Primary/secondary/idiopathic classification of mast cell activation syndrome
  definition_type: DIAGNOSTIC_CRITERIA
  derivation_basis: ESTABLISHED_CRITERIA
  attaches_to:
  - disease#Mast Cell Activation Syndrome
  - has_subtypes#Idiopathic MCAS
  - has_subtypes#Secondary MCAS
  description: >-
    Akin et al. (2010) proposed classifying mast cell activation disorders
    as primary (a clonal mast cell disorder is identified), secondary (a
    well-defined condition is identified as the cause of mast cell
    activation), or idiopathic (neither is found). The classification was
    later extended with combined (both clonal and secondary) and hereditary
    alpha-tryptasemia-associated categories, and is now referred to as the
    ECNM-AIM consortium classification.
  validation_status:
    status: UNVALIDATED
    rationale: >-
      The classification is consensus- and cohort-derived and in wide
      clinical use, but the literature explicitly frames MCAS diagnostic
      criteria as still evolving, with no formal diagnostic-accuracy study
      establishing operating characteristics for the idiopathic/secondary
      distinction itself.
  evidence:
  - reference: PMID:41272881
    reference_title: "Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "They also proposed a classification of mast cell activation disorders: primary (if a clonal mast cell disorder is identified), secondary (if a well-defined condition is identified as the cause of mast cell activation), and idiopathic"
    explanation: States the classification this definition records.
prevalence:
- population: 703 consecutive adult patients referred to a single tertiary center for suspected mast cell disorders
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 4400.0
  notes: >-
    31 of 703 patients referred for suspected mast cell disorders were
    confirmed as idiopathic MCAS after full consensus-criteria workup (4.4%
    of the referred cohort, i.e. 4400 per 100,000 within that cohort). This
    is a proportion within a highly selected referred population, not a
    general-population prevalence; the cohort restriction is carried by the
    `population` field above, not by the prevalence_class band, which
    reports magnitude only.
  evidence:
  - reference: PMID:38056692
    reference_title: "Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among 703 Patients With Suspected Mast Cell Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The overall prevalence of iMCAS was 4.4% in the entire cohort, which indicates that iMCAS is an uncommon condition."
    explanation: Source of the referred-cohort prevalence figure recorded here.
discussions:
- discussion_id: mcas_overdiagnosis_underdiagnosis
  kind: KNOWLEDGE_GAP
  prompt: >-
    How much of the clinical/patient-facing "MCAS" label reflects
    consensus-criteria-confirmed disease versus a broader, unvalidated
    symptom complex, and what does that mean for prevalence estimates?
  attaches_to:
  - disease#Mast Cell Activation Syndrome
  - prevalence#
  rationale: >-
    A 2024 review frames MCAS explicitly as both overdiagnosed (broad
    multisystem symptom complexes labeled MCAS without meeting the three
    consensus criteria) and underdiagnosed (long diagnostic delay before
    confirmation). A large single-center cohort found only 4.4% of patients
    referred for suspected mast cell disorders met strict criteria for
    idiopathic MCAS, far below popular/patient-facing prevalence claims.
    Because no general-population prevalence study exists, any figure cited
    for this entry should be read as bounded to a referred, already-selected
    population, and the underlying question -- how common
    consensus-criteria-confirmed MCAS actually is in an unselected
    population -- remains open.
  evidence:
  - reference: PMID:38851398
    reference_title: "Mast cell activation syndrome: Current understanding and research needs."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "Whether MCAS is a primary syndrome or exists as a constellation of symptoms in the context of known inflammatory, allergic, or clonal disorders associated with systemic mast cell activation is not well understood"
    explanation: >-
      A 2024 JACI review states the open epistemic status of MCAS as a
      distinct clinical entity, motivating this knowledge gap.

📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Address review round 1: prevalence units, mis-cited evidence, missing phenotypes · 2026-09-18T03:44:15Z · View source

Addressed all 1 critical + 4 important findings from the first automated review round on PR #12112: (1) rate_per_100000 was 4.4 instead of the correct 4400.0 (percent x 1000 convention, confirmed against Aspirin-Exacerbated_Respiratory_Disease.yaml precedent) and prevalence_class corrected from NOT_YET_DOCUMENTED to ABOVE_1_IN_1000 since the band reports magnitude, not generalizability; (2)+(3) two pathophysiology evidence items were quoting text unrelated to their claims (an aims statement standing in for PI3K/Akt/mTOR/RAS/MAPK/JAK/STAT signaling content, and a secondary-cause-exclusion sentence standing in for FceRI/MRGPRX2/C3a/C5a receptor content) -- both replaced with real quotes from PMID:42592556 (the paper the deep-research report itself names for this content in its own citation list), which had to be re-fetched after being deleted earlier in the session as apparently uncited; (4) added the missing Respiratory (Dyspnea HP:0002094, Wheezing HP:0030828) and Dermatologic Pruritus (HP:0000989) phenotypes the deep-research report's own organ-system enumeration covers, using quotes already cached from PMID:41272881 and PMID:23179866, wired downstream of the Multisystem Mediator-Driven Symptom Generation node. Also took the reviewer's non-blocking suggestions in the same push per the 'answer a review in one push' rule: dropped an organ-level GO term (GO:0002438) mis-bound to an ORGANISM-scale node, added quote_role: REVIEW_SYNTHESIS to review-article evidence items graded evidence_source: OTHER, and added a Ketotifen treatment entry using already-cached support. Re-validated with just validate-disorders (36/36 snippets verified), just check-folded-hyphens, just check-duplicate-keys, just check-entity-refs, just check-causal-targets, just check-qualifier-terms, just check-enum-values, and the environmental-evidence check.

Create: Mast Cell Activation Syndrome (general/idiopathic + secondary) · 2026-09-18T03:22:13Z · View source

Curated the general MCAS entry (MONDO:0100004), the curation-stub-queue entry stubs/Mast_Cell_Activation_Syndrome.yaml and stubs/Secondary_Mast_Cell_Activation_Syndrome.yaml (both deleted). Deep research via the claude_code provider (research/Mast_Cell_Activation_Syndrome-deep-research-claude_code.md): 27/27 references verified, 0.0 confabulation rate, one off-topic reference (PMID:27571382, a molybdenum-nanosheets materials-science paper, wrongly attributed by the report to the Lyons et al. 2016 Nat Genet hereditary alpha-tryptasemia paper) correctly excluded and replaced with the actual PMID (27749843) found via PubMed search. Term validation flagged one wrong CL binding (CL:0001060, mislabeled 'basophil' but actually a progenitor-cell term) which was not used. Models idiopathic and secondary MCAS as has_subtypes (both MONDO-bound); monoclonal/clonal MCAS remains its own separately-curated entry (Monoclonal_Mast_Cell_Activation_Syndrome.yaml) per the granularity-ladder convention, given its distinct KIT D816V driver and therapy. Hereditary alpha-tryptasemia (TPSAB1 copy-number gain) modeled as a genetic MODIFIER, not a causal lesion. Pathophysiology chain: receptor engagement (IgE-dependent and IgE-independent) -> signaling cascade -> degranulation/mediator release -> multisystem end-organ symptoms. Evidence cites PMID:41272881 (2026 Canadian practical-approach review, primary source for diagnostics/treatment/environmental triggers), PMID:23179866, PMID:21035176 (2010 consensus criteria), PMID:38056692 (703-patient referred-cohort prevalence, 4.4% idiopathic MCAS), PMID:27749843 (HaT genetics), PMID:31576204 (omalizumab case), PMID:38851398 (2024 JACI review, cited for the overdiagnosis/underdiagnosis knowledge-gap discussion). All CURIEs looked up live via runoak at write time after the pre-edit validation hook caught several fabricated/wrong CURIEs (HGNC TPSAB1, HP Angioedema, two ECTO exposure terms, CHEBI montelukast/cromolyn, NCIT omalizumab) on first write attempt -- corrected before the file was actually committed to disk. Validated with just validate-disorders (29/29 snippets verified), just check-folded-hyphens, just check-duplicate-keys, just check-entity-refs, just check-causal-targets, just check-qualifier-terms, just check-enum-values, just check-stubs. This is preparatory work for a planned hEDS-MCAS comorbidity entry.

Claude Code ▸

Mast Cell Activation Syndrome (MCAS): Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 47 citations 2026-09-18T03:08:40.914128

Mast Cell Activation Syndrome (MCAS): Comprehensive Research Report

1. Disease Information

Overview. Mast cell activation syndrome (MCAS) is a clinical entity in which mast cells throughout the body release excessive and/or aberrant quantities of mediators (histamine, tryptase, prostaglandin D2, leukotrienes, heparin, and cytokines) in response to a wide range of physical, chemical, immunologic, and psychological triggers, producing recurrent, episodic, multisystem symptoms — without the mast-cell proliferation seen in mastocytosis (in most cases) (PubMed). As the 2024 JACI review states: "Mast cell activation syndrome is a term applied to several clinical entities that have gained increased attention from patients and medical providers... there are many gaps in knowledge, resulting in confusion about this clinical syndrome. Whether MCAS is a primary syndrome or exists as a constellation of symptoms in the context of known inflammatory, allergic, or clonal disorders associated with systemic mast cell activation is not well understood" (Castells et al., J Allergy Clin Immunol 2024;154:255-263, PMID:38851398) (JACI).

Key identifiers: - MONDO: MONDO:0100004 - ICD-10-CM: D89.4 "Mast cell activation syndrome and related disorders," with subcodes D89.40 (unspecified), D89.41 (monoclonal), D89.42 (idiopathic), D89.43 (secondary), D89.44 (hereditary alpha-tryptasemia), D89.49 (other specified) — codes effective since October 2016 (icd10data.com) - MeSH/related terms: Mastocytosis (D008415); "Mast Cell Activation" concept - Not currently a distinct OMIM phenotype entry (hereditary alpha-tryptasemia, a genetic risk modifier, has its own OMIM entry, #618041)

Synonyms: MCAS; mast cell activation disorder (MCAD); systemic mast cell activation disease (MCAD, per the Molderings nomenclature); idiopathic mast cell activation syndrome; monoclonal mast cell activation syndrome (MMAS).

Data provenance: Most MCAS literature is aggregated disease-level (case series, retrospective cohorts, consensus/expert-opinion documents, and a handful of prospective tryptase/urinary-mediator studies), rather than large EHR/registry-based epidemiology; a recent claims-based study specifically examined rising ICD-10 "unspecified mast cell activation" (D89.40) coding trends in the US, illustrating an emerging EHR data source (PMC).

2. Etiology

Disease causal factors

MCAS is fundamentally a functional/mechanistic disorder of mast cell reactivity rather than a single-gene Mendelian disease. It is now formally subclassified into five clinical phenotypes: primary (clonal) MCAS, driven by clonally aberrant mast cells bearing the somatic KIT D816V mutation and/or aberrant CD25 expression (usually a form of monoclonal MCAS or systemic mastocytosis); secondary MCAS, in which non-clonal mast cells are activated by an identifiable IgE- or non-IgE-mediated trigger (allergy, chronic infection, autoimmune/inflammatory disease); combined (clonal + secondary) MCAS; hereditary alpha-tryptasemia (HαT)-associated MCAS; and idiopathic MCAS, in which no clonal marker or trigger is found (Sciencedirect/JACI-IP).

Genetic risk factors

KIT D816V (somatic, activating tyrosine-kinase mutation) — the molecular hallmark of clonal mast cell disease; present in >90% of systemic mastocytosis but in a minority of MCAS cases. Ultrasensitive detection methods (e.g., SuperRCA, limit of detection 0.001% VAF) have raised detection of KIT D816V to 64% of patients with monoclonal MCAS and 55% of those with bone-marrow mastocytosis, versus 0.01% VAF sensitivity of older ASO-qPCR assays (ASH/Blood). KIT mutations have also been demonstrated in peripheral-blood leukocytes derived from hematopoietic stem cells, not only in mast cells (ScienceDirect).
Hereditary alpha-tryptasemia (HαT) — an autosomal-dominant, highly penetrant germline trait from increased copy number of TPSAB1 (encoding α-tryptase) on chromosome 16, present in 4–6% of the general (Caucasian) population. Lyons et al. (Nat Genet 2016;48:1564-1569, PMID:27571382) described it as "a multisystem disorder associated with increased TPSAB1 copy number," with basal serum tryptase elevated in proportion to α-tryptase-encoding copy number; associated features include systemic hypersensitivity reactions, flushing, pruritus, functional GI disease, connective-tissue abnormalities, and dysautonomia symptoms (WebSearch synthesis of Nat Genet 2016). One extra germline TPSAB1 copy accounts for ~80–90% of HαT cases. HαT is increasingly framed as a genetic modifier rather than a direct cause of MCAS, heightening mediator-symptom severity and anaphylaxis risk when co-occurring with clonal or secondary mast cell disease (Frontiers Allergy 2025).
Familial clustering: Molderings et al. found systemic MCAD in ~46% of first-degree relatives of index patients, versus ~17% background prevalence in the general German population, and proposed that mutated "operator/regulator" genes could predispose to somatic KIT mutation acquisition (Molderings, J Hematol Oncol 2011;4:10, PMID:21418662; Molderings 2013 familial study, PMID:24098785) (PMC/PLOS ONE).
Susceptibility-locus/GWAS-level data specific to non-clonal (idiopathic/secondary) MCAS are essentially absent from the current literature — this is flagged as a major knowledge gap.

Environmental risk factors

Age and sex are not strongly disease-defining (MCAS is reported across the lifespan with a female predominance in most clinical series, mirroring other functional/mast-cell-related syndromes). Established environmental/behavioral triggers precipitating acute activation episodes (rather than causing the underlying susceptibility) include temperature extremes (heat/cold), humidity, sunlight, physical exertion, emotional/physical stress, infections (including COVID-19), alcohol, and specific drug classes (NSAIDs, opioids such as morphine/codeine, radiocontrast agents, some antibiotics) (TMS).

Protective factors

No robust genetic protective variants have been reported specifically for MCAS. Avoidance-based lifestyle modification (trigger avoidance, controlled/graded exercise) is described as reducing episode frequency, though evidence quality is low (mostly expert opinion/case series).

Gene-environment interactions

The clearest documented gene-environment interaction is HαT × trigger exposure: individuals with extra TPSAB1 copies show amplified/more severe reactions to the same immunologic triggers (Hymenoptera venom, drugs, foods) compared with tryptase-normal individuals, consistent with a "modifier" model in which baseline mast-cell mediator reserve (driven by genotype) determines the magnitude of a triggered reaction (Frontiers).

3. Phenotypes

MCAS is defined by episodic, recurrent symptoms involving ≥2 organ systems concurrently, with improvement between episodes and (per consensus criteria) response to anti-mediator therapy (JACI-IP).

Dermatologic (cutaneous) — flushing (suggested HP:0031372 Flushing), urticaria/hives (HP:0001025 Urticaria), pruritus (HP:0000989 Pruritus), angioedema (HP:0100785 Angioedema), dermatographism.

Gastrointestinal — abdominal pain/cramping (HP:0002027 Abdominal pain), nausea (HP:0002018 Nausea), vomiting (HP:0002013 Vomiting), diarrhea (HP:0002014 Diarrhea) and/or constipation (HP:0002019 Constipation), often alternating; gastroesophageal reflux (HP:0002020 Gastroesophageal reflux) — reported in up to 87.5% of HαT-associated MCAS cohorts (PMC); bloating, weight/appetite fluctuation.

Cardiovascular — palpitations (HP:0001962 Palpitations), tachycardia (HP:0001649 Tachycardia), hypotensive syncope (HP:0012ief Syncope, HP:0001278 Orthostatic hypotension), lightheadedness, chest discomfort; vascular anomalies (aneurysms, hemangiomas, telangiectasias) are reported in chronic case series but with weaker evidence (Cleveland Clinic; EDS Clinic synthesis).

Respiratory/naso-ocular — wheezing (HP:0030828 Wheezing), dyspnea (HP:0002094 Dyspnea), nasal congestion, conjunctival injection.

Neurologic/neuropsychiatric — headache (HP:0002315 Headache), dizziness, "brain fog"/cognitive impairment, paresthesia, anxiety and depression — reported in ~62.5% of HαT-MCAS cases in one Greek case series (PMC 2025).

Autonomic — dysautonomia symptoms (~37.5% of the HαT cohort above), overlapping substantially with postural orthostatic tachycardia syndrome (POTS).

Laboratory abnormalities — event-related elevation of serum tryptase; elevated urinary N-methylhistamine and/or 11β-prostaglandin-F2α (metabolite of PGD2).

Phenotype characteristics: Onset is variable (childhood through adulthood, though most clinical series describe adult-onset or adult-diagnosed disease); severity ranges from mild chronic symptoms to anaphylaxis-grade reactions; course is classically episodic/fluctuating rather than steadily progressive, with baseline symptom resolution between flares as a diagnostic requirement (Cleveland Clinic).

Quality-of-life impact: Health-related quality of life is significantly worse in MCAS patients than in healthy controls, particularly in role-function and fatigue domains (PMC).

4. Genetic/Molecular Information

Somatic KIT D816V (HGNC:6342, OMIM *164920): activating point mutation in the tyrosine kinase domain of KIT; gain-of-function, leading to ligand-independent receptor autophosphorylation and constitutive downstream signaling. Present in ~90% of systemic mastocytosis but variably in MCAS; clonality (per WHO criteria) also assessed by aberrant CD25/CD2 expression on marrow mast cells (ScienceDirect).
Germline TPSAB1 copy-number gain (chromosome 16p13.3): HGNC gene for α-tryptase; extra gene copies raise basal serum tryptase and modify mast-cell-disease severity — not itself pathogenic for neoplastic transformation but a clinically important modifier and confounder of tryptase-based MCAS diagnostic algorithms.
Variant classification: KIT D816V is classified pathogenic/gain-of-function per ACMG-type frameworks in the myeloid neoplasm context (as in systemic mastocytosis); in isolated MCAS it is typically reported as a somatic finding of uncertain proliferative significance when found at very low variant allele frequency by ultrasensitive assays.
Allele frequency: TPSAB1 extra-copy trait (HαT) — population frequency ~4–6% in Caucasian cohorts (gnomAD-consistent estimates cited in HαT literature).
Somatic vs germline: KIT D816V — somatic (acquired, hematopoietic); HαT TPSAB1 duplication — germline (inherited, autosomal dominant, highly penetrant for elevated tryptase, incompletely penetrant for symptomatic disease).
Functional consequence: KIT D816V = constitutive gain-of-function kinase activation (ligand-independent). HαT = dosage effect (increased transcription/translation of tryptase, not receptor signaling).
Modifier genes: Molderings proposed heritable "operator/regulator" gene variants predisposing to acquisition of somatic KIT mutations in familial MCAD pedigrees, though specific loci remain unidentified (ScienceDirect).
Epigenetic information: No well-replicated MCAS-specific DNA methylation/histone signature has been established in the literature surveyed; this is an open research gap explicitly noted by the 2024 JACI review.
Chromosomal abnormalities: Not a defining feature of MCAS; large structural variants are relevant mainly to advanced/clonal mastocytosis rather than MCAS per se.

Suggested bindings: gene — hgnc:6342 (KIT); hgnc:12405-adjacent tryptase locus (TPSAB1, HGNC:12157); molecular function — GO term for protein tyrosine kinase activity (GO:0004713) with modifier: GAIN_OF_FUNCTION.

5. Environmental Information

Environmental/toxic factors: No specific toxin or pollutant has been causally linked to MCAS pathogenesis in controlled studies; environmental allergens (pollen, dander, mold) act as secondary-MCAS triggers via IgE-mediated sensitization rather than as etiologic agents of the syndrome itself.

Lifestyle factors: Alcohol consumption is a recurrent, well-documented trigger of acute mast-cell mediator release in MCAS patients; physical exertion has a described bidirectional relationship — both a trigger for reactions and, when graded/controlled, a potential therapeutic/conditioning tool (patientpower.info).

Infectious agents: Acute infections (including COVID-19) and fever are recognized precipitants of symptom flares, presumably via cytokine-mediated mast-cell priming, though MCAS is not caused by a specific pathogen; this is distinct from infection-triggered secondary MCAS.

Stress: Emotional and physical stress (including pain itself) are consistently reported triggers, consistent with neuroimmune mast-cell activation via substance P/CRH-mediated pathways described in the broader mast-cell literature.

6. Mechanism / Pathophysiology

Ordered causal chain (illustrative, drawing on primary vs secondary/idiopathic MCAS):

Initiating lesion — either (a) a somatic KIT D816V mutation arising in a hematopoietic/mast-cell progenitor (primary/clonal MCAS), (b) an IgE-sensitizing exposure or chronic inflammatory/autoimmune process (secondary MCAS), or (c) an unidentified intrinsic mast-cell hyperresponsiveness, potentially amplified by germline TPSAB1 copy-number gain (idiopathic/HαT-associated MCAS) → leads to a population of mast cells with lowered activation threshold and/or increased releasable mediator reserve.
Mast-cell surface receptor engagement — classically FcεRI cross-linking by allergen-bound IgE, but also IgE-independent pathways (MRGPRX2 activation by basic secretagogues/drugs, complement anaphylatoxins C3a/C5a, physical stimuli, endotoxin, free radicals) — leads to intracellular signal transduction.
Downstream signaling cascades — PI3K/Akt/mTOR, RAS/MAPK, and JAK/STAT pathways amplify and coordinate the activation response (PMC 2026) — results in cytoskeletal reorganization and granule trafficking toward the plasma membrane.
Degranulation and de novo mediator synthesis — release of preformed granule contents (histamine, tryptase, heparin, chymase) plus newly synthesized lipid mediators (prostaglandin D2, cysteinyl leukotrienes) and cytokines/chemokines (TNF-α, IL-6, IL-13) (PMC) — leads to local and systemic effects depending on the anatomic site of the activated mast cells.
End-organ effects — histamine and PGD2 → vasodilation/flushing and hypotension; histamine and leukotrienes → smooth-muscle contraction (bronchoconstriction, GI cramping); vascular permeability increase → urticaria/angioedema; autonomic nervous system engagement → tachycardia, presyncope, and dysautonomic symptoms — culminating in the multisystem, episodic clinical picture that defines MCAS.
In clonal/primary disease, this cascade is superimposed on a persistently lower activation threshold conferred by constitutively active KIT signaling, explaining the more severe, spontaneous, and treatment-refractory phenotype often seen in monoclonal MCAS/systemic mastocytosis versus purely reactive secondary/idiopathic disease. This branch point (clonal driver present vs absent) is inferred rather than fully mechanistically demonstrated in idiopathic MCAS, where the primary lesion remains unidentified — a point explicitly flagged as unresolved by Castells et al. 2024 (JACI).

Detail by category: - Molecular pathways: FcεRI signaling; MRGPRX2 (non-IgE secretagogue receptor, relevant to drug-induced pseudoallergy); complement C3a/C5a receptors; KIT/stem-cell-factor axis (constitutively active in D816V-driven disease); PI3K/Akt/mTOR; RAS/MAPK; JAK/STAT. - Cellular processes: Regulated exocytosis (degranulation), eicosanoid biosynthesis (COX/LOX pathway activation), cytokine transcription/secretion, cell migration/homing of mast-cell progenitors. - Protein dysfunction: KIT receptor tyrosine kinase — ligand-independent constitutive activation via D816V substitution in the kinase domain (analogous mechanism to other activation-loop RTK mutations). - Immune involvement: Both IgE-dependent (classic allergic) and IgE-independent innate activation routes contribute; chronic low-grade mast-cell-driven inflammation is proposed to underlie the "idiopathic" subgroup. - Tissue damage mechanisms: Primarily functional (vasoactive/smooth-muscle) rather than destructive/fibrotic in most MCAS (contrasting with the tissue mast-cell infiltration and organ damage of aggressive systemic mastocytosis). - Advanced/omics data: Ultrasensitive digital-PCR-based clonality assays (SuperRCA) represent the most notable recent molecular-profiling advance, improving detection of low-level KIT D816V clones in blood/marrow of MCAS patients (ASH/Blood 2025); broad single-cell/spatial transcriptomic characterization of MCAS-specific (non-neoplastic) mast-cell populations has not yet been published at scale.

Suggested GO/CL terms: GO:0043303 (mast cell degranulation), GO:0033365 (protein localization to organelle — granule trafficking), GO:0002438 (acute inflammatory response to antigenic stimulus), CL:0000097 (mast cell), CL:0001060 (basophil, for comparison), GO:0004713 (protein tyrosine kinase activity, for KIT).

7. Anatomical Structures Affected

Organ level: No single primary organ — MCAS is inherently multisystemic. Skin (integumentary), gastrointestinal tract, cardiovascular system, respiratory tract, and nervous/autonomic system are all commonly involved; secondary/complication-level involvement can include the musculoskeletal system (via connective-tissue/EDS overlap) and reproductive tract (dysmenorrhea reported in some series).

Tissue/cell level: Mast cells (CL:0000097) reside in nearly all vascularized tissues but are especially dense at host-environment interfaces: skin dermis, gastrointestinal submucosa, and respiratory mucosa (UBERON:0002097 skin, UBERON:0001555 digestive tract, UBERON:0001004 respiratory system). Perivascular mast cells mediate cardiovascular symptoms; meningeal/dural mast cells have been proposed (though not firmly established) as contributors to neurologic symptoms.

Subcellular level: Secretory granules (GO:0042582 peroxisome — not applicable; correct term GO:0030141 secretory granule) store preformed histamine/tryptase/heparin; the endoplasmic reticulum and Golgi are involved in de novo eicosanoid and cytokine synthesis; plasma-membrane FcεRI and KIT receptors initiate signaling.

Localization: Symptoms are typically bilateral/systemic rather than lateralized, reflecting the diffuse tissue distribution of mast cells, though localized flares (e.g., unilateral flushing) can occur.

8. Temporal Development

Onset: MCAS can present at any age; most published clinical cohorts describe adult presentation or adult diagnosis, though pediatric HαT/MCAS case series exist (PMC 2021). Onset pattern is typically episodic/acute at the level of individual flares, superimposed on a chronic, often insidious underlying predisposition.

Progression: Disease course is classically non-linear and fluctuating — periods of relative symptom quiescence punctuated by acute flares — rather than following a staged progressive model as in cancer. Primary (clonal) MCAS associated with advancing systemic mastocytosis can show true disease progression (increasing mast-cell burden), whereas idiopathic/secondary MCAS is generally described as a chronic, stable-but-fluctuating condition (researve.com synthesis).

Patterns: Spontaneous and treatment-induced symptomatic remission are both reported; no formalized MCAS-specific staging system exists (unlike systemic mastocytosis, which has WHO-defined subtypes: indolent, smoldering, aggressive, mast cell leukemia).

9. Inheritance and Population

Epidemiology: True population-level prevalence/incidence figures are contested. In a large single-center cohort of 703 patients referred for suspected mast-cell disorders, idiopathic MCAS prevalence was 4.4%, and recent systematic evaluations find that <5% of patients referred for suspected MCAS actually meet strict consensus criteria for primary or idiopathic MCAS after full workup (JACI-IP 2023). This contrasts with much higher, more speculative population estimates (up to double-digit percentages) sometimes cited in older/non-peer-reviewed sources — a discrepancy the field explicitly frames as "overdiagnosed or underdiagnosed?" (JACI-IP 2024). A recent claims-based study documented a rapid rise in "unspecified" ICD-10 mast cell activation (D89.40) coding in the US health system, suggesting increasing clinical recognition (and possible overuse of the unspecified code) rather than a true incidence surge (PMC).

Inheritance pattern: MCAS itself is not classically Mendelian. Where a genetic driver is identified: somatic KIT D816V (clonal MCAS) is acquired, not inherited; hereditary alpha-tryptasemia follows autosomal dominant inheritance with high penetrance for the biochemical trait (elevated tryptase) but variable/incomplete penetrance for symptomatic MCAS-like disease. Family-clustering data (Molderings) suggest a heritable predisposition to somatic KIT mutation acquisition in a subset of familial MCAD, but the operative gene(s) are unidentified (PLOS ONE 2013, PMID:24098785).

Penetrance/expressivity: HαT shows high penetrance for elevated basal tryptase but markedly variable clinical expressivity — many carriers are asymptomatic or mildly symptomatic, while others manifest severe multisystem disease, especially when combined with other mast-cell drivers.

Carrier frequency: HαT trait carrier frequency ~4–6% of Caucasian populations (gnomAD-based estimates in the HαT literature).

Population demographics: No strong ethnic/geographic enrichment has been robustly established for idiopathic MCAS; HαT copy-number variation frequency may differ by ancestry group, though comprehensive population-genetic surveys are limited. Female predominance is reported in most clinical MCAS series, consistent with the pattern seen in related functional syndromes (POTS, fibromyalgia) with which MCAS frequently co-occurs.

10. Diagnostics

Consensus diagnostic criteria (Akin, Valent, Metcalfe, J Allergy Clin Immunol 2010;126:1099-1104, PMID:21035176) — four criteria, all required: 1. "Episodic symptoms consistent with mast cell mediator release affecting two or more organ systems" (skin, GI, cardiovascular, respiratory, naso-ocular). 2. "A decrease in the frequency or severity; or resolution of symptoms with anti-mediator therapy" (H1/H2 antagonists, leukotriene antagonists, mast cell stabilizers). 3. "Evidence of an elevation in a validated urinary or serum marker of mast cell activation" — serum tryptase preferred, documented on ≥2 symptomatic occasions (or once if baseline tryptase >15 ng/mL). 4. "Primary (clonal) and secondary disorders of mast cell activation ruled out" (PMC).

2019/consensus-2 refinement (Valent et al.) formalized a quantitative acute-tryptase-rise formula: an event-related tryptase increase must meet or exceed baseline tryptase (sBT) × 1.2 + 2 ng/mL (i.e., 20% above baseline plus 2 ng/mL), measured within 4 hours of the event versus a baseline drawn ≥24 hours later (De Gruyter "consensus-2").

Laboratory/biomarker testing: - Serum tryptase (acute vs baseline, per above formula) — most specific validated marker. - 24-hour urinary N-methylhistamine (histamine metabolite) and 11β-prostaglandin F2α / 2,3-dinor-11β-PGF2α (PGD2 metabolite) — recommended when tryptase is unavailable or equivocal; in practice, urinary 11β-PGF2α is more frequently elevated than N-methylhistamine in idiopathic MCAS cohorts, and correlates with flushing/pruritus severity (ScienceDirect). NSAID/aspirin use confounds PGF2α results and should be withheld (2 weeks for aspirin, 72 hours for NSAIDs) before collection (Mayo Clinic Labs).

Genetic testing: Peripheral blood and/or bone marrow KIT D816V testing (standard or ultrasensitive digital PCR/SuperRCA) to distinguish clonal from non-clonal disease; TPSAB1 copy-number analysis (droplet digital PCR) for HαT.

Bone marrow evaluation: Reserved for cases with elevated baseline tryptase, cytopenias, organomegaly, or other "B/C findings" suggestive of systemic mastocytosis — includes morphology, immunohistochemistry (CD117, CD25, CD2, tryptase), and molecular KIT testing.

Differential diagnosis (must be excluded before an idiopathic-MCAS label is assigned): hereditary/acquired angioedema, systemic mastocytosis, carcinoid syndrome, pheochromocytoma/paraganglioma, VIPoma, gastrinoma, medullary thyroid carcinoma, hyper-eosinophilic syndrome, aspirin-exacerbated respiratory disease, scombroid poisoning, inflammatory bowel disease, thyroid disease, and idiopathic anaphylaxis (Merck Manual; PMC). A 2024 review frames MCAS, anaphylaxis, and mastocytosis as "interrelated yet distinct conditions within the spectrum of mast cell activation disorders" (PMC "Puzzling Mast Cell Trilogy").

Clinical criteria/screening: No population screening program exists; diagnosis is exclusively clinical + biochemical + (when indicated) histopathologic/molecular, following the stepwise consensus algorithm above.

11. Outcome/Prognosis

MCAS is generally not life-threatening in most non-clonal cases, though anaphylaxis-grade episodes carry acute mortality risk, particularly when compounded by HαT or an underlying clonal disorder. Idiopathic and secondary MCAS typically follow a chronic, fluctuating but non-progressive course; primary (clonal) MCAS prognosis tracks the underlying mastocytosis subtype (indolent systemic mastocytosis has near-normal life expectancy, while advanced/aggressive variants carry significant morbidity/mortality) (Rare Disease Advisor synthesis). Health-related quality of life is significantly reduced compared with healthy controls, most notably in fatigue and role-function domains (PMC). Prognostic factors favoring better outcomes include early diagnosis, trigger identification/avoidance, and adherence to stepwise anti-mediator therapy; comorbid anxiety, depression, and functional GI disease are described as compounding overall disease burden.

12. Treatment

Pharmacotherapy — stepwise approach (per multiple management reviews, e.g., Canadian practical approach, PMC 2025) (PMC): 1. H1-antihistamines (e.g., cetirizine, fexofenadine) — NCIT:C29699-class antihistamine agents; combined with H2-antihistamines (e.g., famotidine, ranitidine-class), since H2 receptors are present on mast cells and cardiovascular tissue, not just gastric parietal cells. 2. Mast cell stabilizers — oral cromolyn sodium (disodium cromoglycate) and ketotifen, added when antihistamines alone are insufficient, particularly for GI-predominant symptoms. 3. Leukotriene receptor antagonists (e.g., montelukast) for respiratory/GI symptoms mediated by cysteinyl leukotrienes. 4. Aspirin in carefully selected, monitored patients (for flushing/PGD2-mediated symptoms, with caution given aspirin's own trigger potential in a subset). 5. Systemic corticosteroids — reserved for severe, refractory cases due to known adverse-effect burden. 6. Omalizumab (anti-IgE monoclonal antibody, NCIT:C1974-class biologic) — for persistent or severe disease refractory to the above; case series document successful use even at low doses in idiopathic MCAS (PMC 2019).

Targeted/clonal-disease-specific therapy (for primary/clonal MCAS with confirmed KIT D816V): - Midostaurin — multikinase/KIT inhibitor; improves quality of life and mediator-related symptoms and can temper IgE-mediated degranulation in advanced systemic mastocytosis. - Avapritinib — selective KIT D816V inhibitor; FDA-approved for indolent and advanced systemic mastocytosis, with ~75% response rate among evaluable advanced-SM patients and marked reduction in mast-cell/disease burden (Springer review, PMID:38217824). Long-term remission is not achieved in all patients despite disease-modifying activity.

Emergency/anaphylaxis management: Epinephrine auto-injector for anaphylaxis-grade reactions (standard of care, NCIT clinical-intervention terms for emergency pharmacotherapy).

Supportive/behavioral: Trigger identification and avoidance counseling; dietary modification for histamine-sensitive individuals (evidence quality low-moderate); psychological support for comorbid anxiety/depression; physical therapy/graded exercise where tolerated, given exercise's dual trigger/therapeutic role.

Experimental/investigational: Ongoing clinical trials of additional KIT inhibitors and biologics targeting mast-cell activation pathways (search ClinicalTrials.gov/WHO ICTRP for current NCT identifiers; specific trial numbers were not extracted in this pass and should be verified via just fetch-reference against ClinicalTrials.gov before KB entry).

Suggested NCIT terms: NCIT:C15986 (Pharmacotherapy, generic action) with therapeutic_agent bound to CHEBI for cetirizine/famotidine/cromolyn/montelukast/omalizumab-class biologics, and NCIT:C20401 (Monoclonal Antibody) for omalizumab's drug-class binding.

13. Prevention

Primary prevention: No vaccine or established primary-prevention strategy exists, since the syndrome largely reflects a fixed genetic/immunologic predisposition (clonal, HαT, or idiopathic hyperresponsiveness). Trigger avoidance (temperature extremes, alcohol, specific drugs/NSAIDs, known allergens) functions as the closest analog to primary prevention of acute episodes.

Secondary prevention: Early recognition and biochemical confirmation (tryptase/urinary-mediator testing) to initiate anti-mediator therapy before symptom chronification; screening first-degree relatives of patients with confirmed HαT or familial MCAD, given the elevated familial recurrence risk documented by Molderings et al.

Tertiary prevention: Structured anti-mediator regimens and (in clonal disease) KIT-targeted therapy to prevent progression to more severe/aggressive mast-cell disease and to reduce anaphylaxis recurrence.

Genetic counseling: Relevant for HαT (autosomal dominant, 50% transmission risk to offspring) and for families with clustering systemic MCAD, though formal genetic-counseling protocols specific to MCAS are not yet standardized in professional-society guidelines.

Prophylaxis: Premedication protocols (antihistamines ± corticosteroids) before procedures, surgery, or contrast administration in known MCAS/mastocytosis patients are widely used clinically, paralleling premedication practice in mastocytosis, though MCAS-specific trial evidence is limited.

14. Other Species / Natural Disease

Human MCAS as defined by consensus criteria (episodic multisystem mediator-release symptoms without obligate clonal proliferation) does not have a well-characterized directly orthologous naturally occurring veterinary disease in the literature surveyed. The closest veterinary analogs are: - Canine and feline mast cell tumors (mastocytoma) — a neoplastic, KIT-mutation-associated disease of skin/subcutis, mechanistically related to clonal mast-cell proliferation (parallel to human mastocytosis) but not a functional-activation syndrome per se; canine mastocytoma is a well-studied KIT-mutation model (internal tandem duplications in exon 11, distinct from human D816V) used in comparative oncology. - Anaphylactic/allergic reactions with mast-cell mediator release occur across essentially all mammalian species studied (rodent, canine, feline, equine), but a discrete "MCAS-equivalent" clinical syndrome has not been formally described outside humans in the sources reviewed here.

Taxonomy: NCBITaxon:9606 (Homo sapiens) is the only species with a formally defined MCAS diagnostic entity to date.

15. Model Organisms

Mouse models: No single validated "MCAS mouse model" exists because MCAS is fundamentally a functional/clinical syndrome rather than a defined molecular lesion in most cases. Relevant model systems instead target mast-cell biology and clonal disease components: - Mast-cell-deficient strains (Kit^W-sh/W-sh, on C57BL/6 or BALB/c background) — used to dissect the necessity of mast cells in allergic/inflammatory phenotypes by comparing responses with and without mast cells; BALB/c-Kit^W-sh/W-sh mice retain near-wild-type airway hyperresponsiveness in some allergic-asthma models, illustrating strong background-strain dependence of mast-cell contribution (Lab Invest 2019). These mice carry confounding hematologic abnormalities (splenomegaly, myeloid/megakaryocytic hyperplasia, neutrophilia) that limit direct translational inference (ScienceDirect). - Humanized KIT D816V xenograft models — e.g., a luciferase-monitored humanized in vivo model of KIT D816V+ advanced systemic mastocytosis, used to test KIT-inhibitor efficacy (avapritinib, midostaurin, nintedanib, CDK4/6 inhibitors) preclinically (PMC); (PMC CDK4/6 synergy study). - Murine anaphylaxis/allergy models (passive systemic anaphylaxis, IgE-mediated airway/skin challenge) — used broadly to study IgE-FcεRI-driven mast-cell degranulation mechanisms relevant to secondary MCAS, reviewed comprehensively in a 2026 PMC article on "Insights Into Complex Murine Models of Allergy and Anaphylaxis" (PMC).

Model characteristics/limitations: Mast-cell-deficient mice recapitulate loss-of-mast-cell-function phenotypes but do not model the gain-of-function/hyperresponsive state that defines MCAS; humanized KIT D816V models capture clonal-disease drug pharmacodynamics but not the broader idiopathic/secondary MCAS phenotype space (no clonal lesion). No zebrafish, Drosophila, or C. elegans model is applicable, since mast cells are a mammalian-specific (vertebrate innate-immune) cell type. In vitro human models — LAD2 and HMC-1 human mast-cell lines, and iPSC-derived mast cells — are used for mechanistic and drug-screening studies of degranulation pathways (FcεRI, MRGPRX2, KIT signaling) relevant to MCAS, though these were not exhaustively re-verified with individual PMIDs in this search pass.

Research applications: Current model systems are best suited to (a) testing KIT-targeted therapeutics for clonal disease, and (b) dissecting IgE/FcεRI and MRGPRX2 degranulation pathways relevant to secondary MCAS; a validated in vivo model specifically recapitulating "idiopathic hyperresponsive mast cell" disease remains an unmet need, consistent with the mechanistic knowledge gaps flagged by Castells et al. 2024.

Key Ontology-Term Suggestions Summary

Category	Suggested term(s)
Disease	MONDO:0100004 (mast cell activation syndrome)
Gene (somatic driver)	hgnc:6342 (KIT)
Gene (modifier)	HGNC gene for TPSAB1 (tryptase alpha/beta 1)
Cell type	CL:0000097 (mast cell)
Biological process	GO:0043303 (mast cell degranulation); GO:0002438 (acute inflammatory response to antigen)
Anatomy	UBERON:0002097 (skin); UBERON:0001555 (digestive tract); UBERON:0001004 (respiratory system)
Phenotypes (HP)	HP:0031372 (Flushing); HP:0001025 (Urticaria); HP:0100785 (Angioedema); HP:0002027 (Abdominal pain); HP:0001649 (Tachycardia); HP:0001278 (Orthostatic hypotension); HP:0002315 (Headache)
Chemicals (CHEBI)	histamine, tryptase (protein, not CHEBI), prostaglandin D2, cysteinyl leukotrienes, heparin
Treatment (NCIT)	NCIT:C15986 (Pharmacotherapy) + therapeutic_agent bindings (antihistamines, cromolyn, omalizumab, KIT inhibitors)

Important Caveats / Gaps for Curation

Controversy is a defining feature of this literature — recent papers explicitly frame MCAS as both "overdiagnosed and underdiagnosed," with true idiopathic-MCAS prevalence (~4–5% of referred patients) far lower than popular/patient-facing sources suggest. Any KB entry should distinguish consensus-criteria-confirmed MCAS from broader "mast cell activation" symptom complexes.
HαT should likely be modeled as a genetic modifier/risk-factor entry (or Inheritance block) rather than folded indistinguishably into MCAS pathophysiology, given its own OMIM/ICD-10 identity (D89.44) and modifier (not causal) role.
Several claims above (EDS/POTS/MCAS "trifecta" prevalence, familial recurrence percentages, quality-of-life effect sizes) come from single cohort studies or narrative reviews rather than large replicated datasets — flag with directness: INDIRECT or appropriate evidence grading during curation, and verify exact PMIDs/snippets via just fetch-reference before use, per repository policy, since this report's citations were compiled from search-engine summaries rather than direct abstract verification for every source.
No clinical-trial NCT identifiers were confirmed in this pass; verify via ClinicalTrials.gov directly before adding clinical_trials: entries.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	27
Resolved	27
Unresolved (possible confabulation)	0
Unverifiable	0
Quoted claims checked	1
Quoted claims found in source	0
Quoted claims not found in source	1
References weighed for topical relevance	27
On topic	23
Off topic	1

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

PMID:38851398 (abstract only): "Mast cell activation syndrome is a term applied to several clinical entities that have gained increased attention from patients and medical providers... there are many gaps in knowledge, resulting in confusion about this clinical syndrome. Whether MCAS is a primary syndrome or exists as a constellation of symptoms in the context of known inflammatory, allergic, or clonal disorders associated with systemic mast cell activation is not well understood"
closest text in source: "Whether MCAS is a primary syndrome or exists as a constellation of symptoms in the context of known inflammatory, allergic, or clonal disorders associated with systemic mast cell activation is not well understood"

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

PMID:27571382 (1 mention) - Colloidal Synthesis of Uniform-Sized Molybdenum Disulfide Nanosheets for Wafer-Scale Flexible Nonvolatile Memory.
shared terms: none

Weighed against this report's own most characteristic terms: mcas, cell, mast, disease, clonal, mastocytosis, systemic, kit, syndrome, activation, symptom, idiopathic, tryptase, secondary, clinical, mast-cell, d816v, primary, patient, trigger.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	35
Resolved	33
Unresolved (possible confabulation)	0
Obsolete	0
Unverifiable	2
Terms whose name was checked	10
Terms named correctly	6
Terms named as a different term	1
Terms whose name is worth a second look	3

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

CL:0001060 (1 mention) - the report calls it "basophil, for comparison"; CL calls it hematopoietic oligopotent progenitor cell, lineage-negative

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

GO:0004713 (2 mentions) - the report calls it "protein tyrosine kinase activity, for KIT"; GO calls it protein tyrosine kinase activity
GO:0033365 (1 mention) - the report calls it "protein localization to organelle — granule trafficking"; GO calls it protein localization to organelle
NCIT:C15986 (2 mentions) - the report calls it "Pharmacotherapy, generic action", "Pharmacotherapy"; NCIT calls it Pharmacotherapy

Terms named inconsistently

The report gives these identifiers more than one name of its own:

NCIT:C15986 - called "Pharmacotherapy, generic action", "Pharmacotherapy"

Ask OpenScientist

OpenScientist Report

Definitions

Subtypes

Comorbidities

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Diagnosis

Prevalence

Source YAML

References & Deep Research

Deep Research

Mast Cell Activation Syndrome (MCAS): Comprehensive Research Report

1. Disease Information

2. Etiology

Disease causal factors

Genetic risk factors

Environmental risk factors

Protective factors

Gene-environment interactions

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Key Ontology-Term Suggestions Summary

Important Caveats / Gaps for Curation

Reference Validation

Quotes not found in the cited source

References that may not be about this subject

Term Validation

Terms the report names something else

Terms whose name is worth a second look

Terms named inconsistently